# A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

> **NCT06192888** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 39 (actual)

## Conditions studied

- Mantle Cell Lymphoma
- MCL

## Interventions

- **DRUG:** Glofitamab
- **DRUG:** Obinutuzumab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT06192888
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-08
- **Primary completion:** 2028-01-08
- **Final completion:** 2028-01-08
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06192888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06192888, "A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06192888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*